{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T02:26:32Z","timestamp":1787711192917,"version":"build-2784847793"},"reference-count":180,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2002,4]]},"DOI":"10.1038\/nrc776","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T08:57:00Z","timestamp":1027673820000},"page":"277-288","source":"Crossref","is-referenced-by-count":1622,"title":["Death and anti-death: tumour resistance to apoptosis"],"prefix":"10.1038","volume":"2","author":[{"given":"Frederik H.","family":"Igney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H.","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFnrc776_CR1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57\u201370 (2000).","journal-title":"Cell"},{"key":"BFnrc776_CR2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0065-230X(08)60744-7","volume":"75","author":"PH Krammer","year":"1998","unstructured":"Krammer, P. H., Galle, P. R., Moller, P. & Debatin, K. M. CD95(APO-1\/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells. Adv. Cancer Res. 75, 251\u2013273 (1998).","journal-title":"Adv. Cancer Res."},{"key":"BFnrc776_CR3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0065-2776(08)60402-2","volume":"71","author":"PH Krammer","year":"1999","unstructured":"Krammer, P. H. CD95(APO-1\/Fas)-mediated apoptosis: live and let die. Adv. Immunol. 71, 163\u2013210 (1999).","journal-title":"Adv. Immunol."},{"key":"BFnrc776_CR4","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S1357-2725(00)00048-0","volume":"32","author":"I Schmitz","year":"2000","unstructured":"Schmitz, I., Kirchhoff, S. & Krammer, P. H. Regulation of death receptor-mediated apoptosis pathways. Int. J. Biochem. Cell Biol. 32, 1123\u20131136 (2000).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"BFnrc776_CR5","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/25387","volume":"396","author":"RM Pitti","year":"1998","unstructured":"Pitti, R. M. et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396, 699\u2013703 (1998).Identification of the decoy receptor DcR3 that inhibits CD95L-induced apoptosis. DcR3 is amplified in tumours.","journal-title":"Nature"},{"key":"BFnrc776_CR6","doi-asserted-by":"crossref","first-page":"13733","DOI":"10.1074\/jbc.274.20.13733","volume":"274","author":"KY Yu","year":"1999","unstructured":"Yu, K. Y. et al. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J. Biol. Chem. 274, 13733\u201313736 (1999).","journal-title":"J. Biol. Chem."},{"key":"BFnrc776_CR7","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1074-7613(00)80211-3","volume":"12","author":"MR Sprick","year":"2000","unstructured":"Sprick, M. R. et al. FADD\/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12, 599\u2013609 (2000).","journal-title":"Immunity"},{"key":"BFnrc776_CR8","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1002\/j.1460-2075.1995.tb00245.x","volume":"14","author":"FC Kischkel","year":"1995","unstructured":"Kischkel, F. C. et al. Cytotoxicity-dependent APO-1 (Fas\/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14, 5579\u20135588 (1995).The first description of the death-inducing signalling complex (DISC) in death receptor-mediated apoptosis.","journal-title":"EMBO J."},{"key":"BFnrc776_CR9","doi-asserted-by":"crossref","first-page":"46639","DOI":"10.1074\/jbc.M105102200","volume":"276","author":"FC Kischkel","year":"2001","unstructured":"Kischkel, F. C. et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J. Biol. Chem. 276, 46639\u201346646 (2001).","journal-title":"J. Biol. Chem."},{"key":"BFnrc776_CR10","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/emboj\/17.6.1675","volume":"17","author":"C Scaffidi","year":"1998","unstructured":"Scaffidi, C. et al. Two CD95 (APO-1\/Fas) signaling pathways. EMBO J. 17, 1675\u20131687 (1998).Clarifies the role of mitochondria in death-receptor-mediated apoptosis.","journal-title":"EMBO J."},{"key":"BFnrc776_CR11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/35048073","volume":"2","author":"N Zamzami","year":"2001","unstructured":"Zamzami, N. & Kroemer, G. The mitochondrion in apoptosis: how Pandora's box opens. Nature Rev. Mol. Cell Biol. 2, 67\u201371 (2001).","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"BFnrc776_CR12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/35048069","volume":"2","author":"JC Martinou","year":"2001","unstructured":"Martinou, J. C. & Green, D. R. Breaking the mitochondrial barrier. Nature Rev. Mol. Cell Biol. 2, 63\u201367 (2001).","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"BFnrc776_CR13","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1146\/annurev.immunol.17.1.781","volume":"17","author":"JC Rathmell","year":"1999","unstructured":"Rathmell, J. C. & Thompson, C. B. The central effectors of cell death in the immune system. Annu. Rev. Immunol. 17, 781\u2013828 (1999).","journal-title":"Annu. Rev. Immunol."},{"key":"BFnrc776_CR14","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/35037722","volume":"407","author":"J Savill","year":"2000","unstructured":"Savill, J. & Fadok, V. Corpse clearance defines the meaning of cell death. Nature 407, 784\u2013788 (2000).","journal-title":"Nature"},{"key":"BFnrc776_CR15","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/sj.cdd.4400525","volume":"6","author":"C Borner","year":"1999","unstructured":"Borner, C. & Monney, L. Apoptosis without caspases: an inefficient molecular guillotine? Cell Death Differ. 6, 497\u2013507 (1999).","journal-title":"Cell Death Differ."},{"key":"BFnrc776_CR16","doi-asserted-by":"publisher","first-page":"14559","DOI":"10.1073\/pnas.93.25.14559","volume":"93","author":"J Xiang","year":"1996","unstructured":"Xiang, J., Chao, D. T. & Korsmeyer, S. J. BAX-induced cell death may not require interleukin 1 \u03b2-converting enzyme-like proteases. Proc. Natl Acad. Sci. USA 93, 14559\u201314563 (1996).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc776_CR17","doi-asserted-by":"crossref","first-page":"14376","DOI":"10.1073\/pnas.97.26.14376","volume":"97","author":"S Sperandio","year":"2000","unstructured":"Sperandio, S., de Belle, I. & Bredesen, D. E. An alternative, nonapoptotic form of programmed cell death. Proc. Natl Acad. Sci. USA 97, 14376\u201314381 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc776_CR18","doi-asserted-by":"crossref","first-page":"8247","DOI":"10.1128\/MCB.21.24.8247-8254.2001","volume":"21","author":"A Krueger","year":"2001","unstructured":"Krueger, A., Baumann, S., Krammer, P. H. & Kirchhoff, S. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol. Cell. Biol. 21, 8247\u20138254 (2001).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc776_CR19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1101\/gad.13.3.239","volume":"13","author":"QL Deveraux","year":"1999","unstructured":"Deveraux, Q. L. & Reed, J. C. IAP family proteins \u2014 suppressors of apoptosis. Genes Dev. 13, 239\u2013252 (1999).","journal-title":"Genes Dev."},{"key":"BFnrc776_CR20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0092-8674(00)00009-X","volume":"102","author":"AM Verhagen","year":"2000","unstructured":"Verhagen, A. M. et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102, 43\u201353 (2000).","journal-title":"Cell"},{"key":"BFnrc776_CR21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0092-8674(00)00008-8","volume":"102","author":"C Du","year":"2000","unstructured":"Du, C., Fang, M., Li, Y., Li, L. & Wang, X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102, 33\u201342 (2000).","journal-title":"Cell"},{"key":"BFnrc776_CR22","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/35077213","volume":"411","author":"GI Evan","year":"2001","unstructured":"Evan, G. I. & Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342\u2013348 (2001).","journal-title":"Nature"},{"key":"BFnrc776_CR23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0092-8674(92)90123-T","volume":"69","author":"GI Evan","year":"1992","unstructured":"Evan, G. I. et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69, 119\u2013128 (1992).","journal-title":"Cell"},{"key":"BFnrc776_CR24","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/359552a0","volume":"359","author":"RP Bissonnette","year":"1992","unstructured":"Bissonnette, R. P., Echeverri, F., Mahboubi, A. & Green, D. R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 359, 552\u2013554 (1992).References 24 and 69\u201373 showed that anti-apoptotic proteins are important oncogenes by reporting the oncogenic potential of BCL2.","journal-title":"Nature"},{"key":"BFnrc776_CR25","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1002\/j.1460-2075.1994.tb06630.x","volume":"13","author":"EA Harrington","year":"1994","unstructured":"Harrington, E. A., Bennett, M. R., Fanidi, A. & Evan, G. I. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J. 13, 3286\u20133295 (1994).","journal-title":"EMBO J."},{"key":"BFnrc776_CR26","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1101\/gad.9.17.2184","volume":"9","author":"P Sabbatini","year":"1995","unstructured":"Sabbatini, P., Lin, J., Levine, A. J. & White, E. Essential role for p53-mediated transcription in E1A-induced apoptosis. Genes Dev. 9, 2184\u20132192 (1995).","journal-title":"Genes Dev."},{"key":"BFnrc776_CR27","doi-asserted-by":"crossref","first-page":"6094","DOI":"10.1038\/sj.onc.1203126","volume":"18","author":"V Stambolic","year":"1999","unstructured":"Stambolic, V., Mak, T. W. & Woodgett, J. R. Modulation of cellular apoptotic potential: contributions to oncogenesis. Oncogene 18, 6094\u20136103 (1999).","journal-title":"Oncogene"},{"key":"BFnrc776_CR28","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1101\/gad.13.22.2905","volume":"13","author":"SR Datta","year":"1999","unstructured":"Datta, S. R., Brunet, A. & Greenberg, M. E. Cellular survival: a play in three Akts. Genes Dev. 13, 2905\u20132927 (1999).","journal-title":"Genes Dev."},{"key":"BFnrc776_CR29","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0955-0674(00)00251-9","volume":"13","author":"SM Frisch","year":"2001","unstructured":"Frisch, S. M. & Screaton, R. A. Anoikis mechanisms. Curr. Opin. Cell Biol. 13, 555\u2013562 (2001).","journal-title":"Curr. Opin. Cell Biol."},{"key":"BFnrc776_CR30","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1083\/jcb.124.4.619","volume":"124","author":"SM Frisch","year":"1994","unstructured":"Frisch, S. M. & Francis, H. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 124, 619\u2013626 (1994).","journal-title":"J. Cell Biol."},{"key":"BFnrc776_CR31","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1093\/emboj\/16.10.2783","volume":"16","author":"A Khwaja","year":"1997","unstructured":"Khwaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P. H. & Downward, J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B\/Akt cellular survival pathway. EMBO J. 16, 2783\u20132793 (1997).","journal-title":"EMBO J."},{"key":"BFnrc776_CR32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1097-2765(00)80456-6","volume":"3","author":"H Puthalakath","year":"1999","unstructured":"Puthalakath, H., Huang, D. C., O'Reilly, L. A., King, S. M. & Strasser, A. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol. Cell 3, 287\u2013296 (1999).","journal-title":"Mol. Cell"},{"key":"BFnrc776_CR33","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1126\/science.1062257","volume":"293","author":"H Puthalakath","year":"2001","unstructured":"Puthalakath, H. et al. Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 293, 1829\u20131832 (2001).","journal-title":"Science"},{"key":"BFnrc776_CR34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00001622-200001000-00013","volume":"12","author":"R Oulton","year":"2000","unstructured":"Oulton, R. & Harrington, L. Telomeres, telomerase, and cancer: life on the edge of genomic stability. Curr. Opin. Oncol. 12, 74\u201381 (2000).","journal-title":"Curr. Opin. Oncol."},{"key":"BFnrc776_CR35","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/13495","volume":"5","author":"WC Hahn","year":"1999","unstructured":"Hahn, W. C. et al. Inhibition of telomerase limits the growth of human cancer cells. Nature Med. 5, 1164\u20131170 (1999).","journal-title":"Nature Med."},{"key":"BFnrc776_CR36","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1101\/gad.13.18.2388","volume":"13","author":"X Zhang","year":"1999","unstructured":"Zhang, X., Mar, V., Zhou, W., Harrington, L. & Robinson, M. O. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 13, 2388\u20132399 (1999).","journal-title":"Genes Dev."},{"key":"BFnrc776_CR37","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0092-8674(00)80762-X","volume":"97","author":"L Chin","year":"1999","unstructured":"Chin, L. et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 97, 527\u2013538 (1999).","journal-title":"Cell"},{"key":"BFnrc776_CR38","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0952-7915(98)80227-6","volume":"10","author":"S Shresta","year":"1998","unstructured":"Shresta, S., Pham, C. T., Thomas, D. A., Graubert, T. A. & Ley, T. J. How do cytotoxic lymphocytes kill their targets? Curr. Opin. Immunol. 10, 581\u2013587 (1998).","journal-title":"Curr. Opin. Immunol."},{"key":"BFnrc776_CR39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/369031a0","volume":"369","author":"D Kagi","year":"1994","unstructured":"Kagi, D. et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369, 31\u201337 (1994).","journal-title":"Nature"},{"key":"BFnrc776_CR40","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/0092-8674(94)90376-X","volume":"76","author":"JW Heusel","year":"1994","unstructured":"Heusel, J. W., Wesselschmidt, R. L., Shresta, S., Russell, J. H. & Ley, T. J. Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 76, 977\u2013987 (1994).","journal-title":"Cell"},{"key":"BFnrc776_CR41","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1002\/eji.1830271250","volume":"27","author":"JP Medema","year":"1997","unstructured":"Medema, J. P. et al. Cleavage of FLICE (caspase-8) by granzyme B during cytotoxic T lymphocyte-induced apoptosis. Eur. J. Immunol. 27, 3492\u20133498 (1997).","journal-title":"Eur. J. Immunol."},{"key":"BFnrc776_CR42","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1084\/jem.192.10.1391","volume":"192","author":"JA Heibein","year":"2000","unstructured":"Heibein, J. A. et al. Granzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members Bid and Bax. J. Exp. Med. 192, 1391\u20131402 (2000).","journal-title":"J. Exp. Med."},{"key":"BFnrc776_CR43","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1084\/jem.177.1.195","volume":"177","author":"E Rouvier","year":"1993","unstructured":"Rouvier, E., Luciani, M. F. & Golstein, P. Fas involvement in Ca2+-independent T cell-mediated cytotoxicity. J. Exp. Med. 177, 195\u2013200 (1993).","journal-title":"J. Exp. Med."},{"key":"BFnrc776_CR44","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.4049\/jimmunol.161.8.3943","volume":"161","author":"JH Li","year":"1998","unstructured":"Li, J. H. et al. The regulation of CD95 ligand expression and function in CTL. J. Immunol. 161, 3943\u20133949 (1998).","journal-title":"J. Immunol."},{"key":"BFnrc776_CR45","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1182\/blood.V98.9.2603","volume":"98","author":"I Herr","year":"2001","unstructured":"Herr, I. & Debatin, K. M. Cellular stress response and apoptosis in cancer therapy. Blood 98, 2603\u20132614 (2001).","journal-title":"Blood"},{"key":"BFnrc776_CR46","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1182\/blood.V98.10.3066","volume":"98","author":"K Stahnke","year":"2001","unstructured":"Stahnke, K., Fulda, S., Friesen, C., Strauss, G. & Debatin, K. M. Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy. Blood 98, 3066\u20133073 (2001).","journal-title":"Blood"},{"key":"BFnrc776_CR47","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0955-0674(00)00216-7","volume":"13","author":"KM Ryan","year":"2001","unstructured":"Ryan, K. M., Phillips, A. C. & Vousden, K. H. Regulation and function of the p53 tumor suppressor protein. Curr. Opin. Cell Biol. 13, 332\u2013337 (2001).","journal-title":"Curr. Opin. Cell Biol."},{"key":"BFnrc776_CR48","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/35096061","volume":"2","author":"CJ Sherr","year":"2001","unstructured":"Sherr, C. J. The INK4A\/ARF network in tumour suppression. Nature Rev. Mol. Cell Biol. 2, 731\u2013737 (2001).","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"BFnrc776_CR49","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0092-8674(95)90513-8","volume":"80","author":"T Miyashita","year":"1995","unstructured":"Miyashita, T. & Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, 293\u2013299 (1995).","journal-title":"Cell"},{"key":"BFnrc776_CR50","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1126\/science.288.5468.1053","volume":"288","author":"E Oda","year":"2000","unstructured":"Oda, E. et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288, 1053\u20131058 (2000).","journal-title":"Science"},{"key":"BFnrc776_CR51","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1097-2765(01)00214-3","volume":"7","author":"K Nakano","year":"2001","unstructured":"Nakano, K. & Vousden, K. H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7, 683\u2013694 (2001).","journal-title":"Mol. Cell"},{"key":"BFnrc776_CR52","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0092-8674(00)00073-8","volume":"102","author":"K Oda","year":"2000","unstructured":"Oda, K. et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102, 849\u2013862 (2000).","journal-title":"Cell"},{"key":"BFnrc776_CR53","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1084\/jem.188.11.2033","volume":"188","author":"M Muller","year":"1998","unstructured":"Muller, M. et al. p53 activates the CD95 (APO-1\/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188, 2033\u20132045 (1998).","journal-title":"J. Exp. Med."},{"key":"BFnrc776_CR54","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jcp.1101","volume":"188","author":"B Guan","year":"2001","unstructured":"Guan, B., Yue, P., Clayman, G. L. & Sun, S. Y. Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene. J. Cell Physiol. 188, 98\u2013105 (2001).","journal-title":"J. Cell Physiol."},{"key":"BFnrc776_CR55","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/ng1097-141","volume":"17","author":"GS Wu","year":"1997","unstructured":"Wu, G. S. et al. KILLER\/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genet. 17, 141\u2013143 (1997).","journal-title":"Nature Genet."},{"key":"BFnrc776_CR56","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/370220a0","volume":"370","author":"C Caelles","year":"1994","unstructured":"Caelles, C., Helmberg, A. & Karin, M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370, 220\u2013223 (1994).","journal-title":"Nature"},{"key":"BFnrc776_CR57","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1126\/science.284.5411.156","volume":"284","author":"MS Soengas","year":"1999","unstructured":"Soengas, M. S. et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 284, 156\u2013159 (1999).","journal-title":"Science"},{"key":"BFnrc776_CR58","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1126\/science.282.5387.290","volume":"282","author":"M Bennett","year":"1998","unstructured":"Bennett, M. et al. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 282, 290\u2013293 (1998).","journal-title":"Science"},{"key":"BFnrc776_CR59","doi-asserted-by":"crossref","first-page":"28191","DOI":"10.1074\/jbc.272.45.28191","volume":"272","author":"H Hug","year":"1997","unstructured":"Hug, H. et al. Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells. J. Biol. Chem. 272, 28191\u201328193 (1997).","journal-title":"J. Biol. Chem."},{"key":"BFnrc776_CR60","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/nm0596-574","volume":"2","author":"C Friesen","year":"1996","unstructured":"Friesen, C., Herr, I., Krammer, P. H. & Debatin, K. M. Involvement of the CD95 (APO-1\/FAS) receptor\/ligand system in drug- induced apoptosis in leukemia cells. Nature Med. 2, 574\u2013577 (1996).Provides evidence that the CD95 system is involved in drug-induced apoptosis and so identifies one particular mechanism by which apoptosis is caused by anticancer drugs at the molecular level.","journal-title":"Nature Med."},{"key":"BFnrc776_CR61","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/sj.cdd.4400419","volume":"5","author":"S Fulda","year":"1998","unstructured":"Fulda, S. et al. Activation of the CD95 (APO-1\/Fas) pathway in drug- and \u03b3-irradiation-induced apoptosis of brain tumor cells. Cell Death Differ. 5, 884\u2013893 (1998).","journal-title":"Cell Death Differ."},{"key":"BFnrc776_CR62","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1172\/JCI119174","volume":"99","author":"M Muller","year":"1997","unstructured":"Muller, M. et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1\/Fas) receptor\/ligand system and involves activation of wild-type p53. J. Clin. Invest. 99, 403\u2013413 (1997).","journal-title":"J. Clin. Invest."},{"key":"BFnrc776_CR63","first-page":"685","volume":"9","author":"M Muller","year":"1998","unstructured":"Muller, M., Scaffidi, C. A., Galle, P. R., Stremmel, W. & Krammer, P. H. The role of p53 and the CD95 (APO-1\/Fas) death system in chemotherapy-induced apoptosis. Eur. Cytokine Netw. 9, 685\u2013686 (1998).","journal-title":"Eur. Cytokine Netw."},{"key":"BFnrc776_CR64","doi-asserted-by":"crossref","first-page":"7826","DOI":"10.1128\/MCB.20.20.7826-7837.2000","volume":"20","author":"ST Eichhorst","year":"2000","unstructured":"Eichhorst, S. T. et al. A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. Mol. Cell. Biol. 20, 7826\u20137837 (2000).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc776_CR65","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1084\/jem.191.1.195","volume":"191","author":"K Newton","year":"2000","unstructured":"Newton, K. & Strasser, A. Ionizing radiation and chemotherapeutic drugs induce apoptosis in lymphocytes in the absence of Fas or FADD\/MORT1 signaling. Implications for cancer therapy. J. Exp. Med. 191, 195\u2013200 (2000).","journal-title":"J. Exp. Med."},{"key":"BFnrc776_CR66","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1126\/science.279.5358.1954","volume":"279","author":"WC Yeh","year":"1998","unstructured":"Yeh, W. C. et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 279, 1954\u20131958 (1998).","journal-title":"Science"},{"key":"BFnrc776_CR67","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/blood.V93.9.3053","volume":"93","author":"S Wesselborg","year":"1999","unstructured":"Wesselborg, S., Engels, I. H., Rossmann, E., Los, M. & Schulze-Osthoff, K. Anticancer drugs induce caspase-8\/FLICE activation and apoptosis in the absence of CD95 receptor\/ligand interaction. Blood 93, 3053\u20133063 (1999).","journal-title":"Blood"},{"key":"BFnrc776_CR68","first-page":"4956","volume":"57","author":"S Fulda","year":"1997","unstructured":"Fulda, S. et al. Betulinic acid triggers CD95 (APO-1\/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res. 57, 4956\u20134964 (1997).","journal-title":"Cancer Res."},{"key":"BFnrc776_CR69","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1126\/science.3874430","volume":"228","author":"Y Tsujimoto","year":"1985","unstructured":"Tsujimoto, Y., Cossman, J., Jaffe, E. & Croce, C. M. Involvement of the BCL-2 gene in human follicular lymphoma. Science 228, 1440\u20131443 (1985).","journal-title":"Science"},{"key":"BFnrc776_CR70","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0092-8674(89)90174-8","volume":"57","author":"TJ McDonnell","year":"1989","unstructured":"McDonnell, T. J. et al. BCL-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57, 79\u201388 (1989).","journal-title":"Cell"},{"key":"BFnrc776_CR71","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/336259a0","volume":"336","author":"JC Reed","year":"1988","unstructured":"Reed, J. C., Cuddy, M., Slabiak, T., Croce, C. M. & Nowell, P. C. Oncogenic potential of BCL-2 demonstrated by gene transfer. Nature 336, 259\u2013261 (1988).","journal-title":"Nature"},{"key":"BFnrc776_CR72","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/348331a0","volume":"348","author":"A Strasser","year":"1990","unstructured":"Strasser, A., Harris, A. W., Bath, M. L. & Cory, S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between MYC and BCL-2. Nature 348, 331\u2013333 (1990).","journal-title":"Nature"},{"key":"BFnrc776_CR73","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/335440a0","volume":"335","author":"DL Vaux","year":"1988","unstructured":"Vaux, D. L., Cory, S. & Adams, J. M. BCL-2 gene promotes haemopoietic cell survival and cooperates with c-MYC to immortalize pre-B cells. Nature 335, 440\u2013442 (1988).","journal-title":"Nature"},{"key":"BFnrc776_CR74","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1084\/jem.193.4.531","volume":"193","author":"SC Kogan","year":"2001","unstructured":"Kogan, S. C. et al. BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRAR\u03b1) to block neutrophil differentiation and initiate acute leukemia. J. Exp. Med. 193, 531\u2013543 (2001).","journal-title":"J. Exp. Med."},{"key":"BFnrc776_CR75","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1172\/JCI117965","volume":"95","author":"M Weller","year":"1995","unstructured":"Weller, M., Malipiero, U., Aguzzi, A., Reed, J. C. & Fontana, A. Protooncogene bcl-2 gene transfer abrogates Fas\/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J. Clin. Invest. 95, 2633\u20132643 (1995).","journal-title":"J. Clin. Invest."},{"key":"BFnrc776_CR76","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","volume":"81","author":"L Campos","year":"1993","unstructured":"Campos, L. et al. High expression of BCL-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81, 3091\u20133096 (1993).","journal-title":"Blood"},{"key":"BFnrc776_CR77","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood.V87.1.265.265","volume":"87","author":"O Hermine","year":"1996","unstructured":"Hermine, O. et al. Prognostic significance of BCL-2 protein expression in aggressive non- Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 87, 265\u2013272 (1996).","journal-title":"Blood"},{"key":"BFnrc776_CR78","first-page":"5407","volume":"52","author":"T Miyashita","year":"1992","unstructured":"Miyashita, T. & Reed, J. C. BCL-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 52, 5407\u20135411 (1992).","journal-title":"Cancer Res."},{"key":"BFnrc776_CR79","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/79542","volume":"6","author":"CA Schmitt","year":"2000","unstructured":"Schmitt, C. A., Rosenthal, C. T. & Lowe, S. W. Genetic analysis of chemoresistance in primary murine lymphomas. Nature Med. 6, 1029\u20131035 (2000).","journal-title":"Nature Med."},{"key":"BFnrc776_CR80","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1182\/blood.V89.8.2986","volume":"89","author":"HW Findley","year":"1997","unstructured":"Findley, H. W., Gu, L., Yeager, A. M. & Zhou, M. Expression and regulation of BCL-2, BCL-XL, and BAX correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood 89, 2986\u20132993 (1997).","journal-title":"Blood"},{"key":"BFnrc776_CR81","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1182\/blood.V87.3.1140.bloodjournal8731140","volume":"87","author":"E Coustan-Smith","year":"1996","unstructured":"Coustan-Smith, E. et al. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood 87, 1140\u20131146 (1996).","journal-title":"Blood"},{"key":"BFnrc776_CR82","doi-asserted-by":"crossref","first-page":"8479","DOI":"10.1073\/pnas.90.18.8479","volume":"90","author":"S Henderson","year":"1993","unstructured":"Henderson, S. et al. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc. Natl Acad. Sci. USA 90, 8479\u20138483 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc776_CR83","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1006\/viro.1994.1309","volume":"201","author":"B Tarodi","year":"1994","unstructured":"Tarodi, B., Subramanian, T. & Chinnadurai, G. Epstein-Barr virus BHRF1 protein protects against cell death induced by DNA-damaging agents and heterologous viral infection. Virology 201, 404\u2013407 (1994).","journal-title":"Virology"},{"key":"BFnrc776_CR84","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nm0397-293","volume":"3","author":"R Sarid","year":"1997","unstructured":"Sarid, R., Sato, T., Bohenzky, R. A., Russo, J. J. & Chang, Y. Kaposi's sarcoma-associated herpesvirus encodes a functional bcl-2 homologue. Nature Med. 3, 293\u2013298 (1997).","journal-title":"Nature Med."},{"key":"BFnrc776_CR85","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/0092-8674(93)90508-N","volume":"74","author":"LH Boise","year":"1993","unstructured":"Boise, L. H. et al. BCL-X, a BCL-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74, 597\u2013608 (1993).","journal-title":"Cell"},{"key":"BFnrc776_CR86","first-page":"2576","volume":"55","author":"MG Dole","year":"1995","unstructured":"Dole, M. G. et al. BCL-XL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res. 55, 2576\u20132582 (1995).","journal-title":"Cancer Res."},{"key":"BFnrc776_CR87","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1073\/pnas.95.10.5724","volume":"95","author":"M Nagane","year":"1998","unstructured":"Nagane, M., Levitzki, A., Gazit, A., Cavenee, W. K. & Huang, H. J. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of BCL-XL and caspase-3-like proteases. Proc. Natl Acad. Sci. USA 95, 5724\u20135729 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc776_CR88","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.V86.5.1903.bloodjournal8651903","volume":"86","author":"AJ Minn","year":"1995","unstructured":"Minn, A. J., Rudin, C. M., Boise, L. H. & Thompson, C. B. Expression of BCL-XL can confer a multidrug resistance phenotype. Blood 86, 1903\u20131910 (1995).","journal-title":"Blood"},{"key":"BFnrc776_CR89","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/blood.V89.2.630","volume":"89","author":"P Zhou","year":"1997","unstructured":"Zhou, P., Qian, L., Kozopas, K. M. & Craig, R. W. MCL-1, a BCL-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 89, 630\u2013643 (1997).","journal-title":"Blood"},{"key":"BFnrc776_CR90","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1182\/blood.V91.3.991.991_991_1000","volume":"91","author":"SH Kaufmann","year":"1998","unstructured":"Kaufmann, S. H. et al. Elevated expression of the apoptotic regulator MCL-1 at the time of leukemic relapse. Blood 91, 991\u20131000 (1998).","journal-title":"Blood"},{"key":"BFnrc776_CR91","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/40657","volume":"388","author":"M Irmler","year":"1997","unstructured":"Irmler, M. et al. Inhibition of death receptor signals by cellular FLIP. Nature 388, 190\u2013195 (1997).Describes the identification of the two forms of cellular FLIP and the expression of FLIP L in melanomas.","journal-title":"Nature"},{"key":"BFnrc776_CR92","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.4049\/jimmunol.165.4.1854","volume":"165","author":"CM Mueller","year":"2000","unstructured":"Mueller, C. M. & Scott, D. W. Distinct molecular mechanisms of Fas resistance in murine B lymphoma cells. J. Immunol. 165, 1854\u20131862 (2000).","journal-title":"J. Immunol."},{"key":"BFnrc776_CR93","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1182\/blood.V94.5.1727","volume":"94","author":"CG Tepper","year":"1999","unstructured":"Tepper, C. G. & Seldin, M. F. Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein\u2013Barr virus tumorigenesis in Burkitt's lymphoma. Blood 94, 1727\u20131737 (1999).","journal-title":"Blood"},{"key":"BFnrc776_CR94","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/386517a0","volume":"386","author":"M Thome","year":"1997","unstructured":"Thome, M. et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386, 517\u2013521 (1997).","journal-title":"Nature"},{"key":"BFnrc776_CR95","doi-asserted-by":"crossref","first-page":"17255","DOI":"10.1074\/jbc.272.28.17255","volume":"272","author":"S Hu","year":"1997","unstructured":"Hu, S., Vincenz, C., Ni, J., Gentz, R. & Dixit, V. M. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J. Biol. Chem. 272, 17255\u201317257 (1997).","journal-title":"J. Biol. Chem."},{"key":"BFnrc776_CR96","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1073\/pnas.94.4.1172","volume":"94","author":"J Bertin","year":"1997","unstructured":"Bertin, J. et al. Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis. Proc. Natl Acad. Sci. USA 94, 1172\u20131176 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc776_CR97","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/jnci\/91.20.1725","volume":"91","author":"M Sturzl","year":"1999","unstructured":"Sturzl, M. et al. Expression of K13\/v-FLIP gene of human herpesvirus 8 and apoptosis in Kaposi's sarcoma spindle cells. J. Natl Cancer Inst. 91, 1725\u20131733 (1999).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrc776_CR98","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.4049\/jimmunol.161.8.3936","volume":"161","author":"T Kataoka","year":"1998","unstructured":"Kataoka, T. et al. FLIP prevents apoptosis induced by death receptors but not by perforin\/granzyme B, chemotherapeutic drugs, and \u03b3 irradiation. J. Immunol. 161, 3936\u20133942 (1998).","journal-title":"J. Immunol."},{"key":"BFnrc776_CR99","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1084\/jem.190.7.1033","volume":"190","author":"JP Medema","year":"1999","unstructured":"Medema, J. P., de Jong, J., van Hall, T., Melief, C. J. & Offringa, R. Immune escape of tumors in vivo by expression of cellular FLICE- inhibitory protein. J. Exp. Med. 190, 1033\u20131038 (1999).Showed that expression of FLIP is a mechanism for immune escape of tumors in vivo.","journal-title":"J. Exp. Med."},{"key":"BFnrc776_CR100","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1084\/jem.190.7.1025","volume":"190","author":"M Djerbi","year":"1999","unstructured":"Djerbi, M. et al. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J. Exp. Med. 190, 1025\u20131032 (1999).","journal-title":"J. Exp. Med."},{"key":"BFnrc776_CR101","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.4049\/jimmunol.167.8.4230","volume":"167","author":"MA Taylor","year":"2001","unstructured":"Taylor, M. A. et al. Inhibition of the death receptor pathway by cFLIP confers partial engraftment of MHC class I-deficient stem cells and reduces tumor clearance in perforin-deficient mice. J. Immunol. 167, 4230\u20134237 (2001).","journal-title":"J. Immunol."},{"key":"BFnrc776_CR102","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1126\/science.7510905","volume":"263","author":"J Cheng","year":"1994","unstructured":"Cheng, J. et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263, 1759\u20131762 (1994).","journal-title":"Science"},{"key":"BFnrc776_CR103","first-page":"3870","volume":"56","author":"GP Midis","year":"1996","unstructured":"Midis, G. P., Shen, Y. & Owen-Schaub, L. B. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res. 56, 3870\u20133874 (1996).","journal-title":"Cancer Res."},{"key":"BFnrc776_CR104","first-page":"1282","volume":"7","author":"S Ugurel","year":"2001","unstructured":"Ugurel, S., Rappl, G., Tilgen, W. & Reinhold, U. Increased soluble CD95 (sFas\/CD95) serum level correlates with poor prognosis in melanoma patients. Clin. Cancer Res. 7, 1282\u20131286 (2001).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc776_CR105","first-page":"1521","volume":"79","author":"CD Gerharz","year":"1999","unstructured":"Gerharz, C. D. et al. Resistance to CD95 (APO-1\/Fas)-mediated apoptosis in human renal cell carcinomas: an important factor for evasion from negative growth control. Lab. Invest. 79, 1521\u20131534 (1999).","journal-title":"Lab. Invest."},{"key":"BFnrc776_CR106","first-page":"2759","volume":"61","author":"W Roth","year":"2001","unstructured":"Roth, W. et al. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res. 61, 2759\u20132765 (2001).","journal-title":"Cancer Res."},{"key":"BFnrc776_CR107","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1172\/JCI14123","volume":"108","author":"JC Reed","year":"2001","unstructured":"Reed, J. C. The Survivin saga goes in vivo. J. Clin. Invest. 108, 965\u2013969 (2001).","journal-title":"J. Clin. Invest."},{"key":"BFnrc776_CR108","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm0897-917","volume":"3","author":"G Ambrosini","year":"1997","unstructured":"Ambrosini, G., Adida, C. & Altieri, D. C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nature Med. 3, 917\u2013921 (1997).Identifies the IAP-family member survivin and shows that some IAPs are overexpressed in cancers.","journal-title":"Nature Med."},{"key":"BFnrc776_CR109","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(05)70294-4","volume":"351","author":"C Adida","year":"1998","unstructured":"Adida, C., Berrebi, D., Peuchmaur, M., Reyes-Mugica, M. & Altieri, D. C. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351, 882\u2013883 (1998).","journal-title":"Lancet"},{"key":"BFnrc776_CR110","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1172\/JCI13345","volume":"108","author":"D Grossman","year":"2001","unstructured":"Grossman, D. et al. Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J. Clin. Invest. 108, 991\u2013999 (2001).","journal-title":"J. Clin. Invest."},{"key":"BFnrc776_CR111","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1073\/pnas.98.2.635","volume":"98","author":"D Grossman","year":"2001","unstructured":"Grossman, D., Kim, P. J., Schechner, J. S. & Altieri, D. C. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc. Natl Acad. Sci. USA 98, 635\u2013640 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc776_CR112","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1172\/JCI200112983","volume":"108","author":"M Mesri","year":"2001","unstructured":"Mesri, M., Wall, N. R., Li, J., Kim, R. W. & Altieri, D. C. Cancer gene therapy using a survivin mutant adenovirus. J. Clin. Invest 108, 981\u2013990 (2001).","journal-title":"J. Clin. Invest"},{"key":"BFnrc776_CR113","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1182\/blood.V93.11.3601","volume":"93","author":"J Dierlamm","year":"1999","unstructured":"Dierlamm, J. et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 93, 3601\u20133609 (1999).","journal-title":"Blood"},{"key":"BFnrc776_CR114","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0960-9822(00)00781-8","volume":"10","author":"D Vucic","year":"2000","unstructured":"Vucic, D., Stennicke, H. R., Pisabarro, M. T., Salvesen, G. S. & Dixit, V. M. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr. Biol. 10, 1359\u20131366 (2000).","journal-title":"Curr. Biol."},{"key":"BFnrc776_CR115","doi-asserted-by":"crossref","first-page":"11515","DOI":"10.1073\/pnas.201398198","volume":"98","author":"JP Medema","year":"2001","unstructured":"Medema, J. P. et al. Blockade of the granzyme B\/perforin pathway through overexpression of the serine protease inhibitor PI-9\/SPI-6 constitutes a mechanism for immune escape by tumors. Proc. Natl Acad. Sci. USA 98, 11515\u201311520 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc776_CR116","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1126\/science.275.5302.967","volume":"275","author":"N Rampino","year":"1997","unstructured":"Rampino, N. et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275, 967\u2013969 (1997).","journal-title":"Science"},{"key":"BFnrc776_CR117","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1182\/blood.V91.8.2991.2991_2991_2997","volume":"91","author":"JP Meijerink","year":"1998","unstructured":"Meijerink, J. P. et al. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood 91, 2991\u20132997 (1998).","journal-title":"Blood"},{"key":"BFnrc776_CR118","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/blood.V92.1.230.413k17_230_233","volume":"92","author":"JJ Molenaar","year":"1998","unstructured":"Molenaar, J. J. et al. Microsatellite instability and frameshift mutations in BAX and transforming growth factor-\u03b2 RII genes are very uncommon in acute lymphoblastic leukemia in vivo but not in cell lines. Blood 92, 230\u2013233 (1998).","journal-title":"Blood"},{"key":"BFnrc776_CR119","first-page":"4471","volume":"55","author":"S Krajewski","year":"1995","unstructured":"Krajewski, S. et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 55, 4471\u20134478 (1995).","journal-title":"Cancer Res."},{"key":"BFnrc776_CR120","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/385637a0","volume":"385","author":"C Yin","year":"1997","unstructured":"Yin, C., Knudson, C. M., Korsmeyer, S. J. & Van Dyke, T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385, 637\u2013640 (1997).","journal-title":"Nature"},{"key":"BFnrc776_CR121","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1172\/JCI118715","volume":"97","author":"RC Bargou","year":"1996","unstructured":"Bargou, R. C. et al. Overexpression of the death-promoting gene Bax-\u03b1 which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J. Clin. Invest. 97, 2651\u20132659 (1996).","journal-title":"J. Clin. Invest."},{"key":"BFnrc776_CR122","doi-asserted-by":"crossref","first-page":"10872","DOI":"10.1073\/pnas.190210897","volume":"97","author":"Y Ionov","year":"2000","unstructured":"Ionov, Y., Yamamoto, H., Krajewski, S., Reed, J. C. & Perucho, M. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc. Natl Acad. Sci. USA 97, 10872\u201310877 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc776_CR123","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/35051606","volume":"409","author":"MS Soengas","year":"2001","unstructured":"Soengas, M. S. et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409, 207\u2013211 (2001).Showed that metastatic melanomas acquire resistance to chemotherapy by losing APAF1 expression.","journal-title":"Nature"},{"key":"BFnrc776_CR124","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/75007","volume":"6","author":"T Teitz","year":"2000","unstructured":"Teitz, T. et al. Caspase-8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nature Med. 6, 529\u2013535 (2000).","journal-title":"Nature Med."},{"key":"BFnrc776_CR125","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/nm1296-1361","volume":"2","author":"S Strand","year":"1996","unstructured":"Strand, S. et al. Lymphocyte apoptosis induced by CD95 (APO-1\/Fas) ligand-expressing tumor cells \u2014 a mechanism of immune evasion? Nature Med. 2, 1361\u20131366 (1996).Showed that tumour cells can evade immune attack by downregulation of the CD95 receptor and killing of lymphocytes through expression of CD95L.","journal-title":"Nature Med."},{"key":"BFnrc776_CR126","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/ijc.2910570314","volume":"57","author":"P Moller","year":"1994","unstructured":"Moller, P. et al. Expression of APO-1 (CD95), a member of the NGF\/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer 57, 371\u2013377 (1994).","journal-title":"Int. J. Cancer"},{"key":"BFnrc776_CR127","first-page":"415","volume":"69","author":"F Leithauser","year":"1993","unstructured":"Leithauser, F. et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor\/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest. 69, 415\u2013429 (1993).","journal-title":"Lab. Invest."},{"key":"BFnrc776_CR128","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s001090100244","volume":"79","author":"M Volkmann","year":"2001","unstructured":"Volkmann, M. et al. Loss of CD95 expression is linked to most but not all p53 mutants in European hepatocellular carcinoma. J. Mol. Med. 79, 594\u2013600 (2001).","journal-title":"J. Mol. Med."},{"key":"BFnrc776_CR129","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/emboj\/18.7.1824","volume":"18","author":"J Peli","year":"1999","unstructured":"Peli, J. et al. Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas. EMBO J. 18, 1824\u20131831 (1999).","journal-title":"EMBO J."},{"key":"BFnrc776_CR130","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1084\/jem.189.7.1063","volume":"189","author":"T Maeda","year":"1999","unstructured":"Maeda, T. et al. Fas gene mutation in the progression of adult T cell leukemia. J. Exp. Med. 189, 1063\u20131071 (1999).","journal-title":"J. Exp. Med."},{"key":"BFnrc776_CR131","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/blood.V90.11.4266","volume":"90","author":"TH Landowski","year":"1997","unstructured":"Landowski, T. H., Qu, N., Buyuksal, I., Painter, J. S. & Dalton, W. S. Mutations in the Fas antigen in patients with multiple myeloma. Blood 90, 4266\u20134270 (1997).","journal-title":"Blood"},{"key":"BFnrc776_CR132","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4049\/jimmunol.156.1.13","volume":"156","author":"I Cascino","year":"1996","unstructured":"Cascino, I., Papoff, G., De Maria, R., Testi, R. & Ruberti, G. Fas\/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J. Immunol. 156, 13\u201317 (1996).","journal-title":"J. Immunol."},{"key":"BFnrc776_CR133","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood.V98.1.194","volume":"98","author":"SE Straus","year":"2001","unstructured":"Straus, S. E. et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 98, 194\u2013200 (2001).","journal-title":"Blood"},{"key":"BFnrc776_CR134","first-page":"4942","volume":"61","author":"MS Shin","year":"2001","unstructured":"Shin, M. S. et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res. 61, 4942\u20134946 (2001).","journal-title":"Cancer Res."},{"key":"BFnrc776_CR135","first-page":"1688","volume":"7","author":"MJ Fisher","year":"2001","unstructured":"Fisher, M. J. et al. Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin. Cancer Res. 7, 1688\u20131697 (2001).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc776_CR136","first-page":"3513","volume":"58","author":"SI Pai","year":"1998","unstructured":"Pai, S. I. et al. Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res 58, 3513\u20133518 (1998).","journal-title":"Cancer Res"},{"key":"BFnrc776_CR137","first-page":"5683","volume":"59","author":"SH Lee","year":"1999","unstructured":"Lee, S. H. et al. Alterations of the DR5\/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res. 59, 5683\u20135686 (1999).","journal-title":"Cancer Res."},{"key":"BFnrc776_CR138","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/35055027","volume":"3","author":"P Liston","year":"2001","unstructured":"Liston, P. et al. Identification of XAF1 as an antagonist of XIAP anti-caspase activity. Nature Cell Biol. 3, 128\u2013133 (2001).","journal-title":"Nature Cell Biol."},{"key":"BFnrc776_CR139","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1126\/science.7973635","volume":"266","author":"SW Lowe","year":"1994","unstructured":"Lowe, S. W. et al. p53 status and the efficacy of cancer therapy in vivo. Science 266, 807\u2013810 (1994).Showed that tumours can acquire resistance to therapy by mutation or deficiency of p53.","journal-title":"Science"},{"key":"BFnrc776_CR140","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1073\/pnas.90.12.5742","volume":"90","author":"JM Lee","year":"1993","unstructured":"Lee, J. M. & Bernstein, A. p53 mutations increase resistance to ionizing radiation. Proc. Natl Acad. Sci. USA 90, 5742\u20135746 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc776_CR141","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nm0796-811","volume":"2","author":"T Aas","year":"1996","unstructured":"Aas, T. et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med. 2, 811\u2013814 (1996).","journal-title":"Nature Med."},{"key":"BFnrc776_CR142","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1172\/JCI6863","volume":"104","author":"F Bunz","year":"1999","unstructured":"Bunz, F. et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104, 263\u2013269 (1999).","journal-title":"J. Clin. Invest."},{"key":"BFnrc776_CR143","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1101\/gad.13.20.2670","volume":"13","author":"CA Schmitt","year":"1999","unstructured":"Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R. & Lowe, S. W. INK4A\/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 13, 2670\u20132677 (1999).","journal-title":"Genes Dev."},{"key":"BFnrc776_CR144","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1097-2765(01)00367-7","volume":"8","author":"Y Samuels-Lev","year":"2001","unstructured":"Samuels-Lev, Y. et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell 8, 781\u2013794 (2001).","journal-title":"Mol. Cell"},{"key":"BFnrc776_CR145","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/385544a0","volume":"385","author":"A Kauffmann-Zeh","year":"1997","unstructured":"Kauffmann-Zeh, A. et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 385, 544\u2013548 (1997).","journal-title":"Nature"},{"key":"BFnrc776_CR146","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1126\/science.276.5320.1848","volume":"276","author":"HW Chang","year":"1997","unstructured":"Chang, H. W. et al. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science 276, 1848\u20131850 (1997).","journal-title":"Science"},{"key":"BFnrc776_CR147","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/5042","volume":"21","author":"L Shayesteh","year":"1999","unstructured":"Shayesteh, L. et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genet. 21, 99\u2013102 (1999).","journal-title":"Nature Genet."},{"key":"BFnrc776_CR148","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1073\/pnas.96.4.1563","volume":"96","author":"K Podsypanina","year":"1999","unstructured":"Podsypanina, K. et al. Mutation of Pten\/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl Acad. Sci. USA 96, 1563\u20131568 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc776_CR149","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0960-9822(07)00488-5","volume":"8","author":"A Suzuki","year":"1998","unstructured":"Suzuki, A. et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8, 1169\u20131178 (1998).","journal-title":"Curr. Biol."},{"key":"BFnrc776_CR150","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ng0497-356","volume":"15","author":"PA Steck","year":"1997","unstructured":"Steck, P. A. et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23. 3 that is mutated in multiple advanced cancers. Nature Genet. 15, 356\u2013362 (1997).","journal-title":"Nature Genet."},{"key":"BFnrc776_CR151","doi-asserted-by":"crossref","first-page":"9267","DOI":"10.1073\/pnas.89.19.9267","volume":"89","author":"JQ Cheng","year":"1992","unstructured":"Cheng, J. Q. et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine\/threonine kinases, is amplified in human ovarian carcinomas. Proc. Natl Acad. Sci. USA 89, 9267\u20139271 (1992).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc776_CR152","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/5289","volume":"17","author":"A Persidis","year":"1999","unstructured":"Persidis, A. Cancer multidrug resistance. Nature Biotechnol. 17, 94\u201395 (1999).","journal-title":"Nature Biotechnol."},{"key":"BFnrc776_CR153","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1360704","volume":"258","author":"SP Cole","year":"1992","unstructured":"Cole, S. P. et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258, 1650\u20131654 (1992).","journal-title":"Science"},{"key":"BFnrc776_CR154","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.V93.3.1075","volume":"93","author":"RW Johnstone","year":"1999","unstructured":"Johnstone, R. W., Cretney, E. & Smyth, M. J. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 93, 1075\u20131085 (1999).","journal-title":"Blood"},{"key":"BFnrc776_CR155","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1073\/pnas.95.12.7024","volume":"95","author":"MJ Smyth","year":"1998","unstructured":"Smyth, M. J., Krasovskis, E., Sutton, V. R. & Johnstone, R. W. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc. Natl Acad. Sci. USA 95, 7024\u20137029 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc776_CR156","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0006-2952(00)00391-9","volume":"60","author":"V Bours","year":"2000","unstructured":"Bours, V. et al. Nuclear factor-\u03baB, cancer, and apoptosis. Biochem. Pharmacol. 60, 1085\u20131089 (2000).","journal-title":"Biochem. Pharmacol."},{"key":"BFnrc776_CR157","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.1038\/sj.onc.1203221","volume":"18","author":"B Rayet","year":"1999","unstructured":"Rayet, B. & Gelinas, C. Aberrant REL\/NF-\u03baB genes and activity in human cancer. Oncogene 18, 6938\u20136947 (1999).","journal-title":"Oncogene"},{"key":"BFnrc776_CR158","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1038\/sj.onc.1201735","volume":"16","author":"KM Wood","year":"1998","unstructured":"Wood, K. M., Roff, M. & Hay, R. T. Defective I\u03baB\u03b1 in Hodgkin cell lines with constitutively active NF-\u03baB. Oncogene 16, 2131\u20132139 (1998).","journal-title":"Oncogene"},{"key":"BFnrc776_CR159","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/9511","volume":"5","author":"T Sethi","year":"1999","unstructured":"Sethi, T. et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nature Med. 5, 662\u2013668 (1999).","journal-title":"Nature Med."},{"key":"BFnrc776_CR160","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1074-7613(00)80011-4","volume":"10","author":"R Catlett-Falcone","year":"1999","unstructured":"Catlett-Falcone, R. et al. Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10, 105\u2013115 (1999).","journal-title":"Immunity"},{"key":"BFnrc776_CR161","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/35037747","volume":"407","author":"DW Nicholson","year":"2000","unstructured":"Nicholson, D. W. From bench to clinic with apoptosis-based therapeutic agents. Nature 407, 810\u2013816 (2000).","journal-title":"Nature"},{"key":"BFnrc776_CR162","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/5517","volume":"5","author":"H Walczak","year":"1999","unstructured":"Walczak, H. et al. Tumoricidal activity of tumor necrosis factor-related apoptosis- inducing ligand in vivo. Nature Med. 5, 157\u2013163 (1999).Showed that a recombinant form of TRAIL (LZ-TRAIL) could suppress tumour growth in vivo without affecting normal tissue.","journal-title":"Nature Med."},{"key":"BFnrc776_CR163","first-page":"734","volume":"59","author":"MM Keane","year":"1999","unstructured":"Keane, M. M., Ettenberg, S. A., Nau, M. M., Russell, E. K. & Lipkowitz, S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 59, 734\u2013741 (1999).","journal-title":"Cancer Res."},{"key":"BFnrc776_CR164","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1073\/pnas.030545097","volume":"97","author":"AM Chinnaiyan","year":"2000","unstructured":"Chinnaiyan, A. M. et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl Acad. Sci. USA 97, 1754\u20131759 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc776_CR165","first-page":"847","volume":"60","author":"M Nagane","year":"2000","unstructured":"Nagane, M. et al. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res. 60, 847\u2013853 (2000).","journal-title":"Cancer Res."},{"key":"BFnrc776_CR166","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0277-5379(86)90107-0","volume":"22","author":"L Fransen","year":"1986","unstructured":"Fransen, L., Van der Heyden, J., Ruysschaert, R. & Fiers, W. Recombinant tumor necrosis factor: its effect and its synergism with interferon-\u03b3 on a variety of normal and transformed human cell lines. Eur. J. Cancer Clin. Oncol. 22, 419\u2013426 (1986).","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"BFnrc776_CR167","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.1992.10.1.52","volume":"10","author":"D Lienard","year":"1992","unstructured":"Lienard, D., Ewalenko, P., Delmotte, J. J., Renard, N. & Lejeune, F. J. High-dose recombinant tumor necrosis factor alpha in combination with interferon \u03b3 and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 10, 52\u201360 (1992).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc776_CR168","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/sj.leu.2402169","volume":"15","author":"PT Daniel","year":"2001","unstructured":"Daniel, P. T., Wieder, T., Sturm, I. & Schulze-Osthoff, K. The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia 15, 1022\u20131032 (2001).","journal-title":"Leukemia"},{"key":"BFnrc776_CR169","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/12469","volume":"5","author":"HM Ellerby","year":"1999","unstructured":"Ellerby, H. M. et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nature Med. 5, 1032\u20131038 (1999).","journal-title":"Nature Med."},{"key":"BFnrc776_CR170","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nm0298-232","volume":"4","author":"B Jansen","year":"1998","unstructured":"Jansen, B. et al. BCL-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nature Med. 4, 232\u2013234 (1998).","journal-title":"Nature Med."},{"key":"BFnrc776_CR171","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2000.18.9.1812","volume":"18","author":"JS Waters","year":"2000","unstructured":"Waters, J. S. et al. Phase I clinical and pharmacokinetic study of BCL-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 18, 1812\u20131823 (2000).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc776_CR172","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/15079","volume":"17","author":"JK Taylor","year":"1999","unstructured":"Taylor, J. K., Zhang, Q. Q., Wyatt, J. R. & Dean, N. M. Induction of endogenous BCL-xS through the control of Bcl-X pre-mRNA splicing by antisense oligonucleotides. Nature Biotechnol. 17, 1097\u20131100 (1999).","journal-title":"Nature Biotechnol."},{"key":"BFnrc776_CR173","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/nsb0901-746","volume":"8","author":"PD Zamore","year":"2001","unstructured":"Zamore, P. D. RNA interference: listening to the sound of silence. Nature Struct. Biol. 8, 746\u2013750 (2001).","journal-title":"Nature Struct. Biol."},{"key":"BFnrc776_CR174","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/35094077","volume":"1","author":"AN Bullock","year":"2001","unstructured":"Bullock, A. N. & Fersht, A. R. Rescuing the function of mutant p53. Nature Rev. Cancer 1, 68\u201376 (2001).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc776_CR175","first-page":"4210","volume":"55","author":"C Yang","year":"1995","unstructured":"Yang, C., Cirielli, C., Capogrossi, M. C. & Passaniti, A. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res. 55, 4210\u20134213 (1995).","journal-title":"Cancer Res."},{"key":"BFnrc776_CR176","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/(SICI)1097-0215(19970502)71:3<377::AID-IJC13>3.0.CO;2-D","volume":"71","author":"K Asgari","year":"1997","unstructured":"Asgari, K. et al. Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. Int. J. Cancer 71, 377\u2013382 (1997).","journal-title":"Int. J. Cancer"},{"key":"BFnrc776_CR177","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/7410","volume":"5","author":"CY Wang","year":"1999","unstructured":"Wang, C. Y., Cusack, J. C. Jr, Liu, R. & Baldwin, A. S. Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-\u03baB. Nature Med. 5, 412\u2013417 (1999).","journal-title":"Nature Med."},{"key":"BFnrc776_CR178","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0092-8674(00)00187-2","volume":"103","author":"DC Huang","year":"2000","unstructured":"Huang, D. C. & Strasser, A. BH3-only proteins-essential initiators of apoptotic cell death. Cell 103, 839\u2013842 (2000).","journal-title":"Cell"},{"key":"BFnrc776_CR179","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0092-8674(00)80405-5","volume":"91","author":"SR Datta","year":"1997","unstructured":"Datta, S. R. et al. AKT phosphorylation of BAD couples survival signals to the cell- intrinsic death machinery. Cell 91, 231\u2013241 (1997).","journal-title":"Cell"},{"key":"BFnrc776_CR180","volume-title":"Untersuchungen \u00fcber die Entwicklungsgeschichte der Geburtshelferkroete (Alytes obstetricians)","author":"C Vogt","year":"1842","unstructured":"Vogt, C. Untersuchungen \u00fcber die Entwicklungsgeschichte der Geburtshelferkroete (Alytes obstetricians) (Jent & Gassmann, Solothurn, 1842)."}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrc776.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc776","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc776.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:41:37Z","timestamp":1684467697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrc776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":180,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["BFnrc776"],"URL":"https:\/\/doi.org\/10.1038\/nrc776","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,4]]}}}